Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis

Haematologica

Volumn 96, Issue 2, 2011, Pages 291-297

  Kröger, Nicolaus ^a   Zabelina, Tatjana ^a   van Biezen, Anja ^b   Brand, Ronald ^b   Niederwieser, Dietger ^c   Martino, Rodrigo ^d   Lim, Zi Yi ^e   Onida, Francesco ^f   Schmid, Christoph ^g   Garderet, Laurent ^h   Robin, Marie ⁱ   van Gelder, Michael ^j   Marks, Reinhard ^k   Symeonidis, Argiris ^l   Kobbe, Guido ^m   de Witte, Theo ⁿ  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF MILAN   (Italy)

^g Department of Hematology/Oncology ^*  (Germany)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF FREIBURG   (Germany)

^l UNIVERSITY OF PATRAS   (Greece)

^m UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Allogeneic stem cell transplantation; Bone marrow fibrosis; Engraftment; Myelodysplastic syndromes

Indexed keywords

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; OVERALL SURVIVAL; PROGNOSIS; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PRIMARY MYELOFIBROSIS; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79551643588     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031229     Document Type: Article

References (15)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89 (6):2097-88.
2. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594-603.
3. Lambertenghi-Deliliers G, Annaloro C, Oriani A, Solgio D, Pozzoli E, Polli E. Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. Ann Hematol. 1993; 66(2):85-91.
4. Verhoef GE, De Wolf-Peeters C, Ferrant A, Deprez S, Meeus P, Stuhl M, et al. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Haematol. 1991;63(5):235-41.
5. Maschek H, Georgii A, Kaloutsi V, Bandecar K, Kressel MG, Choritz H, et al Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol. 1992;48(4):208-14.
6. Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2008;22(2):313-22.
7. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-62.
8. Scott BL, Storer BE, Greene JE, Hackman RC, Appelbaum FR, Deeg HJ. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant. 2007; 13(3):345-54.
9. Lambertenghi-Deliliers G, Orazi A, Luksch Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol. 1991;78(2):161-6.
10. Marisavljevic D, Rolovic Z, Cemerikic V, Boskovic D, Colovic M. Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. Med Oncol. 2004;21(4):325-31.
11. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res. 2001;25(10):829-38.
12. Rajantie J, Sale GE, Deeg HJ, Amos D, Appelbaum F, Storb R, et al. Adverse effect of severe marrow fibrosis on haematological recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood. 1986;67(6):1693-7.
13. Soll E, Massumoto C, Clift RA, Buckner CD, Appelbaum FR, Storb R, et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood. 1995;86(12): 4667-73.
14. Reilly JT, Barnett D, Dolan G, Forrest P, Eastham J, Smith A. Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol. 1993;83(1):58-62.
15. Kimura A, Katoh O, Hyodo H, Kuramoto A. Transforming growth factor beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol. 1989;72(4):486-91.